Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is one of the best up and coming penny stocks to buy. On February 2, Acurx Pharmaceuticals announced that the United States Patent and Trademark Office granted a new patent, US 12,534,470, covering its DNA Polymerase IIIC inhibitors. This patent includes compositions-of-matter, methods of use, and pharmaceutical compositions, reinforcing the company’s intellectual property for its ACX-375C program.

To date, Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) has secured four US patents alongside international grants in Israel, Japan, India, and Australia, with further country-level applications currently under review. Executive Chairman Robert J. DeLuccia stated that this patent extends protection for the company’s AI-supported drug discovery platform, which aims to transform the treatment of life-threatening infections.

Recent preclinical data suggests that microbiome selectivity may be a class effect of these novel compounds when compared to antibiotics like linezolid. While the lead inhibitor, ibezapolstat, is Phase 3-ready for treating C. difficile, these newer preclinical compounds show potential for systemic absorption via oral and parenteral administration. The company’s pipeline targets various serious conditions, including MRSA, community-acquired bacterial pneumonia, bacteremia, and inhalational anthrax. Acurx focuses on developing a new class of small-molecule antibiotics that inhibit the Gram-positive-specific enzyme DNA polymerase IIIC to cause bacterial cell death.

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company that develops antibiotics to treat bacterial infections in the US. The company’s lead antibiotic candidate is ibezapolstat, which targets the polymerase IIIC enzyme.